Allied Market Research

2024

Raloxifene Hydrochloride Market

Raloxifene Hydrochloride Market Size, Share, Competitive Landscape and Trend Analysis Report by Dosage Form and by End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals

Select an option
Author's: | Roshan Deshmukh
Publish Date:

Get Sample to Email

Raloxifene hydrochloride is an oral medication intended for the prevention of osteoporosis in postmenopausal women. In addition, raloxifene hydrochloride medications are also used for the reduction of risk and treatment of invasive breast cancer. Raloxifene hydrochloride is sold under the brand name of Evista among all others. Key factors driving the growth of this market are rise in the number of diseases such as osteoporosis and breast cancer coupled with the increasing geriatric population. However, side effects such as hot flashes, dizziness, leg pain and others associated with raloxifene hydrochloride medicines may restrain the market growth. Moreover, growing awareness regarding these medications and increase in R&D investment for the development of novel therapeutic drugs will create lucrative opportunities for key market players.

The raloxifene hydrochloride market is segmented based on dosage form, end user and region. Based on dosage form this market is segmented into capsule and tablet. Further, based on end user this market is segmented into medical uses, chemical industry and others. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the market included in the report are Eli Lilly and Company, InvaGen Pharmaceuticals Inc, Actavis, Camber Pharmaceuticals Inc., Jiangsu Hengrui Medicine Co. Ltd., Teva Pharmaceutical Industries Ltd., Sanika Chemical Pvt Ltd., Taj Pharmaceutical Limited, Cadila Pharmaceuticals Ltd., and Zydus Alidac.

Key Benefits

  • The study provides an in-depth analysis of the global raloxifene hydrochloride market, with current trends and future estimations to elucidate the imminent investment pockets.
  • It presents a quantitative analysis¬†to enable the stakeholders to capitalize on prevailing market opportunities.
  • Extensive analysis of the market by product type elucidates the various forms of available raloxifene hydrochloride type.
  • Key players are profiled and their strategies are analyzed thoroughly, which predict the competitive outlook of the market.
  • By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Raloxifene Hydrochloride Market Report Highlights

Aspects Details
icon_5
By Dosage Form
  • Capsule
  • Tablet
icon_6
By End User
  • Pharmacy
  • Chemical Industry
  • Others
icon_7
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
icon_8
Key Market Players

Actavis, InvaGen Pharmaceuticals Inc., Sanika Chemical Pvt Ltd., Camber Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Cadila Pharmaceuticals Ltd., Zydus Alidac, Jiangsu Hengrui Medicine Co. Ltd., Eli Lilly and Company, Taj Pharmaceutical Limited

Loading Table Of Content...

Individual sections of the reports are available for purchase.
Would you like to see a breakdown of prices by section?

Raloxifene Hydrochloride Market

Global Opportunity Analysis and Industry Forecast, 2023-2032